1
|
Villalobos-Sánchez E, García-Ruiz D, Camacho-Villegas TA, Canales-Aguirre AA, Gutiérrez-Ortega A, Muñoz-Medina JE, Elizondo-Quiroga DE. In Vitro Antiviral Activity of Nordihydroguaiaretic Acid against SARS-CoV-2. Viruses 2023; 15:v15051155. [PMID: 37243241 DOI: 10.3390/v15051155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 05/06/2023] [Accepted: 05/08/2023] [Indexed: 05/28/2023] Open
Abstract
The coronavirus infectious disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been spreading rapidly worldwide, creating a pandemic. This article describes the evaluation of the antiviral activity of nordihydroguaiaretic acid (NDGA), a molecule found in Creosote bush (Larrea tridentata) leaves, against SARS-CoV-2 in vitro. A 35 µM concentration of NDGA was not toxic to Vero cells and exhibited a remarkable inhibitory effect on the SARS-CoV-2 cytopathic effect, viral plaque formation, RNA replication, and expression of the SARS-CoV-2 spike glycoprotein. The 50% effective concentration for NDGA was as low as 16.97 µM. Our results show that NDGA could be a promising therapeutic candidate against SARS-CoV-2.
Collapse
Affiliation(s)
- Erendira Villalobos-Sánchez
- Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| | - Daniel García-Ruiz
- Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| | - Tanya A Camacho-Villegas
- CONACYT, Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| | - Alejandro A Canales-Aguirre
- Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| | - Abel Gutiérrez-Ortega
- Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| | - José E Muñoz-Medina
- Coordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguros Social, México City 27170, Mexico
| | - Darwin E Elizondo-Quiroga
- Medical and Pharmaceutical Biotechnology Unit, Center of Research and Assistance in Technology and Design of the State of Jalisco, Guadalajara 44270, Mexico
| |
Collapse
|
2
|
Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, Yagi S, Mbala-Kingebeni P, Kapetshi J, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Ahmed AA, Ganesh V, Tamhankar M, Patterson JL, Ndembi N, Mbanya D, Kaptue L, McArthur C, Muñoz-Medina JE, Gonzalez-Bonilla CR, López S, Arias CF, Arevalo S, Miller S, Stone M, Busch M, Hsieh K, Messenger S, Wadford DA, Rodgers M, Cloherty G, Faria NR, Thézé J, Pybus OG, Neto Z, Morais J, Taveira N, Hackett JR, Chiu CY. Author Correction: Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. Nat Microbiol 2020; 5:525. [PMID: 31965087 PMCID: PMC7608365 DOI: 10.1038/s41564-020-0671-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Xianding Deng
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Asmeeta Achari
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Scot Federman
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Guixia Yu
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Sneha Somasekar
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Inês Bártolo
- Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
| | - Shigeo Yagi
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | | | - Jimmy Kapetshi
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | | | - Asim A Ahmed
- Boston Children's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Vijay Ganesh
- Massachussetts General Hospital, Boston, MA, USA
| | - Manasi Tamhankar
- Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Jean L Patterson
- Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Nicaise Ndembi
- Institute for Human Virology Nigeria, Abuja, Nigeria.,Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Dora Mbanya
- Universite de Yaoundé I, Yaoundé, Cameroon.,University of Bamenda, Bamenda, Cameroon
| | | | | | | | | | - Susana López
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Carlos F Arias
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Shaun Arevalo
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Steve Miller
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Mars Stone
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Michael Busch
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Kristina Hsieh
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | - Sharon Messenger
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | - Debra A Wadford
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | | | | | - Nuno R Faria
- Department of Zoology, University of Oxford, Oxford, UK
| | - Julien Thézé
- Department of Zoology, University of Oxford, Oxford, UK
| | | | - Zoraima Neto
- Angolan National Institute of Health Research, Luanda, Angola
| | - Joana Morais
- Angolan National Institute of Health Research, Luanda, Angola
| | - Nuno Taveira
- Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Instituto Universitário Egas Moniz (IUEM), Monte de Caparica, Portugal
| | | | - Charles Y Chiu
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. .,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA. .,Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
3
|
Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, Yagi S, Mbala-Kingebeni P, Kapetshi J, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Ahmed AA, Ganesh V, Tamhankar M, Patterson JL, Ndembi N, Mbanya D, Kaptue L, McArthur C, Muñoz-Medina JE, Gonzalez-Bonilla CR, López S, Arias CF, Arevalo S, Miller S, Stone M, Busch M, Hsieh K, Messenger S, Wadford DA, Rodgers M, Cloherty G, Faria NR, Thézé J, Pybus OG, Neto Z, Morais J, Taveira N, R Hackett J, Chiu CY. Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. Nat Microbiol 2020; 5:443-454. [PMID: 31932713 PMCID: PMC7047537 DOI: 10.1038/s41564-019-0637-9] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Accepted: 11/08/2019] [Indexed: 12/27/2022]
Abstract
Metagenomic next-generation sequencing (mNGS), the shotgun sequencing of RNA and DNA from clinical samples, has proved useful for broad-spectrum pathogen detection and the genomic surveillance of viral outbreaks. An additional target enrichment step is generally needed for high-sensitivity pathogen identification in low-titre infections, yet available methods using PCR or capture probes can be limited by high cost, narrow scope of detection, lengthy protocols and/or cross-contamination. Here, we developed metagenomic sequencing with spiked primer enrichment (MSSPE), a method for enriching targeted RNA viral sequences while simultaneously retaining metagenomic sensitivity for other pathogens. We evaluated MSSPE for 14 different viruses, yielding a median tenfold enrichment and mean 47% (±16%) increase in the breadth of genome coverage over mNGS alone. Virus detection using MSSPE arboviral or haemorrhagic fever viral panels was comparable in sensitivity to specific PCR, demonstrating 95% accuracy for the detection of Zika, Ebola, dengue, chikungunya and yellow fever viruses in plasma samples from infected patients. Notably, sequences from re-emerging and/or co-infecting viruses that have not been specifically targeted a priori, including Powassan and Usutu, were successfully enriched using MSSPE. MSSPE is simple, low cost, fast and deployable on either benchtop or portable nanopore sequencers, making this method directly applicable for diagnostic laboratory and field use. This study describes a new method that improves the sensitivity of viral detection compared with next-generation sequencing and enables the detection of emerging flaviviruses not specifically targeted a priori. Metagenomic sequencing with spiked primer enrichment is simple, low cost, fast and deployable on either benchtop or portable nanopore sequencers, making it applicable for diagnostic laboratory and field use.
Collapse
Affiliation(s)
- Xianding Deng
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Asmeeta Achari
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Scot Federman
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Guixia Yu
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Sneha Somasekar
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Inês Bártolo
- Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
| | - Shigeo Yagi
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | | | - Jimmy Kapetshi
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | | | - Asim A Ahmed
- Boston Children's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Vijay Ganesh
- Massachussetts General Hospital, Boston, MA, USA
| | - Manasi Tamhankar
- Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Jean L Patterson
- Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Nicaise Ndembi
- Institute for Human Virology Nigeria, Abuja, Nigeria.,Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Dora Mbanya
- Universite de Yaoundé I, Yaoundé, Cameroon.,University of Bamenda, Bamenda, Cameroon
| | | | | | | | | | - Susana López
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Carlos F Arias
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Shaun Arevalo
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Steve Miller
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Mars Stone
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Michael Busch
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Kristina Hsieh
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | - Sharon Messenger
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | - Debra A Wadford
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA
| | | | | | - Nuno R Faria
- Department of Zoology, University of Oxford, Oxford, UK
| | - Julien Thézé
- Department of Zoology, University of Oxford, Oxford, UK
| | | | - Zoraima Neto
- Angolan National Institute of Health Research, Luanda, Angola
| | - Joana Morais
- Angolan National Institute of Health Research, Luanda, Angola
| | - Nuno Taveira
- Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Instituto Universitário Egas Moniz (IUEM), Monte de Caparica, Portugal
| | | | - Charles Y Chiu
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. .,UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA. .,Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
4
|
Toledo-Rueda W, Rosas-Murrieta NH, Muñoz-Medina JE, González-Bonilla CR, Reyes-Leyva J, Santos-López G. Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017. Infect Drug Resist 2018; 11:1751-1756. [PMID: 30349332 PMCID: PMC6188218 DOI: 10.2147/idr.s153154] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Background Influenza causes high rates of morbidity and mortality. Genetic variability of influenza viruses generates resistance to antivirals, which are of two types, since they act on two different viral targets: adamantanes, which block the M2 ion channel, and the neuraminidase (NA) inhibitors. Methods In Mexico, the available studies on the antiviral resistance of circulating influenza strains are scarce, so this work undertook an analysis of the Mexican sequences reported in public gene banks to perform a systematic analysis of the antiviral resistance markers on both M2 and NA. In all, 284 M2 sequences and 423 NA sequences were retrieved from three genetic databases (sequences from 2000 to 2017 were considered). Results The resistance markers to M2 blockers were present in 100% of H1N1 pdm2009, 83.6% of H3N2, and 5.8% of seasonal H1N1 sequences. Two resistance markers conferring resistance to NA inhibitors were present in seasonal H1N1 sequences, H275Y (50.0%) and N70S (33.3%). None of these viruses had both resistance markers, which are associated with oseltamivir resistance. The more frequent resistance marker in H1N1 pdm2009 NA sequences was H275Y, present in 3.6%, while S247N was present in 0.30%. Only one of the resistance-associated markers (Q136K) in NA (1.5%) was present in the analyzed H3N2 sequences, while sequences of influenza B virus did not present resistance markers to NA inhibitors. Some influenza A H1N1 pdm2009 sequences (1.8%) presented resistance markers to both M2 and NA. Conclusion Based on the present analysis, 7.1% of the all serotypes of influenza virus A sequences analyzed in Mexico from 2000 to 2017 have mutations conferring resistance to NA inhibitors. Because of this, and the limited availability of influenza drugs, it is necessary to increase the epidemiological surveillance, including molecular analysis, which will provide data such as the presence of changes associated with antiviral resistance.
Collapse
Affiliation(s)
- William Toledo-Rueda
- Laboratory of Molecular Biology and Virology, Eastern Biomedical Research Center, Mexican Institute of Social Security, Metepec, Puebla, Mexico, .,Postgraduate in Chemical Sciences, Autonomous University of Puebla, Puebla, Mexico
| | - Nora H Rosas-Murrieta
- Laboratory of Biochemistry and Molecular Biology, Chemistry Center, Institute of Science, Autonomous University of Puebla, Puebla, Mexico
| | - José E Muñoz-Medina
- Division of Laboratories for Surveillance and Epidemiological Research, Coordination of Epidemiological Surveillance, Mexican Institute of Social Security, Mexico City, Mexico
| | - César R González-Bonilla
- Division of Laboratories for Surveillance and Epidemiological Research, Coordination of Epidemiological Surveillance, Mexican Institute of Social Security, Mexico City, Mexico
| | - Julio Reyes-Leyva
- Laboratory of Molecular Biology and Virology, Eastern Biomedical Research Center, Mexican Institute of Social Security, Metepec, Puebla, Mexico,
| | - Gerardo Santos-López
- Laboratory of Molecular Biology and Virology, Eastern Biomedical Research Center, Mexican Institute of Social Security, Metepec, Puebla, Mexico,
| |
Collapse
|
5
|
Thézé J, Li T, du Plessis L, Bouquet J, Kraemer MUG, Somasekar S, Yu G, de Cesare M, Balmaseda A, Kuan G, Harris E, Wu CH, Ansari MA, Bowden R, Faria NR, Yagi S, Messenger S, Brooks T, Stone M, Bloch EM, Busch M, Muñoz-Medina JE, González-Bonilla CR, Wolinsky S, López S, Arias CF, Bonsall D, Chiu CY, Pybus OG. Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. Cell Host Microbe 2018; 23:855-864.e7. [PMID: 29805095 PMCID: PMC6006413 DOI: 10.1016/j.chom.2018.04.017] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 03/27/2018] [Accepted: 04/26/2018] [Indexed: 02/06/2023]
Abstract
The Zika virus (ZIKV) epidemic in the Americas established ZIKV as a major public health threat and uncovered its association with severe diseases, including microcephaly. However, genetic epidemiology in some at-risk regions, particularly Central America and Mexico, remains limited. We report 61 ZIKV genomes from this region, generated using metagenomic sequencing with ZIKV-specific enrichment, and combine phylogenetic, epidemiological, and environmental data to reconstruct ZIKV transmission. These analyses revealed multiple independent ZIKV introductions to Central America and Mexico. One introduction, likely from Brazil via Honduras, led to most infections and the undetected spread of ZIKV through the region from late 2014. Multiple lines of evidence indicate biannual peaks of ZIKV transmission in the region, likely driven by varying local environmental conditions for mosquito vectors and herd immunity. The spatial and temporal heterogeneity of ZIKV transmission in Central America and Mexico challenges arbovirus surveillance and disease control measures.
Collapse
Affiliation(s)
- Julien Thézé
- Department of Zoology, University of Oxford, Oxford, UK
| | - Tony Li
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | | | - Jerome Bouquet
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Moritz U G Kraemer
- Department of Zoology, University of Oxford, Oxford, UK; Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA
| | - Sneha Somasekar
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Guixia Yu
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA
| | - Mariateresa de Cesare
- Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Angel Balmaseda
- Laboratory Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua
| | - Guillermina Kuan
- Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua
| | - Eva Harris
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
| | - Chieh-Hsi Wu
- Department of Statistics, University of Oxford, Oxford, UK
| | - M Azim Ansari
- Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Rory Bowden
- Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Nuno R Faria
- Department of Zoology, University of Oxford, Oxford, UK
| | - Shigeo Yagi
- California Department of Public Health, Richmond, CA, USA
| | | | - Trevor Brooks
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Mars Stone
- Blood Systems Research Institute, San Francisco, CA, USA
| | - Evan M Bloch
- Department of Pathology, Johns Hopkins University School of Medcine, Baltimore, MD, USA
| | - Michael Busch
- Blood Systems Research Institute, San Francisco, CA, USA
| | - José E Muñoz-Medina
- División de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Cesar R González-Bonilla
- División de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Steven Wolinsky
- Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Susana López
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Carlos F Arias
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - David Bonsall
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Charles Y Chiu
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, USA.
| | - Oliver G Pybus
- Department of Zoology, University of Oxford, Oxford, UK.
| |
Collapse
|
6
|
Pardavé-Alejandre HD, Alvarado-Yaah JE, Pompa-Mera EN, Muñoz-Medina JE, Sárquiz-Martínez B, Santacruz-Tinoco CE, Manning-Cela RG, Ortíz-Navarrete V, López-Macías C, González-Bonilla CR. Autodisplay of an avidin with biotin-binding activity on the surface of Escherichia coli. Biotechnol Lett 2018; 40:591-600. [PMID: 29357100 DOI: 10.1007/s10529-018-2507-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Accepted: 01/08/2018] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To display a recombinant avidin fused to the autotransporter ShdA to bind biotinylated molecules on the surface of Escherichia coli. RESULTS Two chimeric protein constructs containing avidin fused to the autotransporter ShdA were expressed on the surface of Escherichia coli DH5α. One fusion protein contained 476 amino acids of the ShdA α and β domains, whereas the second consisted of a 314 amino acid from α and truncated β domains. Protein production was verified by SDS-PAGE using an antibody to the molecular FLAG-tag. The surface display of the avidin-shdA fusion protein was confirmed by confocal microscopy and flow cytometry analysis, and the biotin-binding activity was evaluated by fluorescence microscopy and flow cytometry using biotin-4-fluorescein and biotinylated-ovalbumin (OVA). CONCLUSIONS Expression of a recombinant avidin with biotin-binding activity on the surface of E. coli was achieved using the autotransporter ShdA. This system is an alternative to bind biotinylated molecules to E. coli.
Collapse
Affiliation(s)
- H D Pardavé-Alejandre
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México
| | - J E Alvarado-Yaah
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México
| | - E N Pompa-Mera
- Unidad de Investigación en Enfermedades Infecciosas y Parasitarias, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, México
| | - J E Muñoz-Medina
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México
| | - B Sárquiz-Martínez
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México
| | - C E Santacruz-Tinoco
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México
| | - R G Manning-Cela
- Depto. de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Mexico
| | - V Ortíz-Navarrete
- Depto. de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Mexico
| | - C López-Macías
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, México
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - C R González-Bonilla
- Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, México.
| |
Collapse
|
7
|
Sarquiz-Martínez B, González-Bonilla CR, Santacruz-Tinoco CE, Muñoz-Medina JE, Pardavé-Alejandre HD, Barbosa-Cabrera E, Ramírez-González JE, Díaz-Quiñonez JA. Differential Detection of Enterovirus and Herpes Simplex Virus in Cerebrospinal Fluid by Real-Time RT-PCR. Intervirology 2017; 60:118-124. [PMID: 28954265 DOI: 10.1159/000480508] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 08/21/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Enterovirus (EV) and herpes simplex virus 1 and 2 (HSV1 and HSV2) are the main etiologic agents of central nervous system infections. Early laboratory confirmation of these infections is performed by viral culture of the cerebrospinal fluid (CSF), or the detection of specific antibodies in serum (e.g., HSV). The sensitivity of viral culture ranges from 65 to 75%, with a recovery time varying from 3 to 10 days. Serological tests are faster and easy to carry out, but they exhibit cross-reactivity between HSV1 and HSV2. Although molecular techniques are more sensitive (sensitivity >95%), they are more expensive and highly susceptible to cross-contamination. METHODS A real-time RT-PCR for the detection of EV, HSV1, and HSV2 was compared with end-point nested PCR. RESULTS We tested 87 CSF samples of patients with a clinical diagnosis of viral meningitis or encephalitis. Fourteen samples were found to be positive by RT-PCR, but only 8 were positive by end-point PCR. The RT-PCR showed a specificity range of 94-100%, the negative predictive value was 100%, and the positive predictive value was 62, 100, and 28% for HSV1, HSV2, and EV, respectively. CONCLUSION Real-time RT-PCR detected EV, HSV1, and HSV2 with a higher sensitivity and specificity than end-point nested RT-PCR.
Collapse
Affiliation(s)
- Brenda Sarquiz-Martínez
- Laboratorio Central de Epidemiología, Instituto Mexicano de Seguridad Social (IMSS), Mexico City, México
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Faria NR, Quick J, Claro IM, Thézé J, de Jesus JG, Giovanetti M, Kraemer MUG, Hill SC, Black A, da Costa AC, Franco LC, Silva SP, Wu CH, Raghwani J, Cauchemez S, du Plessis L, Verotti MP, de Oliveira WK, Carmo EH, Coelho GE, Santelli ACFS, Vinhal LC, Henriques CM, Simpson JT, Loose M, Andersen KG, Grubaugh ND, Somasekar S, Chiu CY, Muñoz-Medina JE, Gonzalez-Bonilla CR, Arias CF, Lewis-Ximenez LL, Baylis SA, Chieppe AO, Aguiar SF, Fernandes CA, Lemos PS, Nascimento BLS, Monteiro HAO, Siqueira IC, de Queiroz MG, de Souza TR, Bezerra JF, Lemos MR, Pereira GF, Loudal D, Moura LC, Dhalia R, França RF, Magalhães T, Marques ET, Jaenisch T, Wallau GL, de Lima MC, Nascimento V, de Cerqueira EM, de Lima MM, Mascarenhas DL, Neto JPM, Levin AS, Tozetto-Mendoza TR, Fonseca SN, Mendes-Correa MC, Milagres FP, Segurado A, Holmes EC, Rambaut A, Bedford T, Nunes MRT, Sabino EC, Alcantara LCJ, Loman NJ, Pybus OG. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature 2017; 546:406-410. [PMID: 28538727 DOI: 10.1038/nature22401] [Citation(s) in RCA: 377] [Impact Index Per Article: 53.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 05/02/2017] [Indexed: 12/21/2022]
Abstract
Transmission of Zika virus (ZIKV) in the Americas was first confirmed in May 2015 in northeast Brazil. Brazil has had the highest number of reported ZIKV cases worldwide (more than 200,000 by 24 December 2016) and the most cases associated with microcephaly and other birth defects (2,366 confirmed by 31 December 2016). Since the initial detection of ZIKV in Brazil, more than 45 countries in the Americas have reported local ZIKV transmission, with 24 of these reporting severe ZIKV-associated disease. However, the origin and epidemic history of ZIKV in Brazil and the Americas remain poorly understood, despite the value of this information for interpreting observed trends in reported microcephaly. Here we address this issue by generating 54 complete or partial ZIKV genomes, mostly from Brazil, and reporting data generated by a mobile genomics laboratory that travelled across northeast Brazil in 2016. One sequence represents the earliest confirmed ZIKV infection in Brazil. Analyses of viral genomes with ecological and epidemiological data yield an estimate that ZIKV was present in northeast Brazil by February 2014 and is likely to have disseminated from there, nationally and internationally, before the first detection of ZIKV in the Americas. Estimated dates for the international spread of ZIKV from Brazil indicate the duration of pre-detection cryptic transmission in recipient regions. The role of northeast Brazil in the establishment of ZIKV in the Americas is further supported by geographic analysis of ZIKV transmission potential and by estimates of the basic reproduction number of the virus.
Collapse
Affiliation(s)
- N R Faria
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK.,Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - J Quick
- Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
| | - I M Claro
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | - J Thézé
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK
| | - J G de Jesus
- Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia, Brazil
| | - M Giovanetti
- Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia, Brazil.,University of Rome Tor Vergata, Rome, Italy
| | - M U G Kraemer
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK.,Harvard Medical School, Boston, Massachusetts, USA.,Boston Children's Hospital, Boston, Massachusetts, USA
| | - S C Hill
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK
| | - A Black
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.,Department of Epidemiology, University of Washington, Seattle, Washington, USA
| | - A C da Costa
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | - L C Franco
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - S P Silva
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - C-H Wu
- Department of Statistics, University of Oxford, Oxford OX1 3LB, UK
| | - J Raghwani
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK
| | - S Cauchemez
- Mathematical Modelling of Infectious Diseases and Center of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris, France.,Centre National de la Recherche Scientifique, URA3012, Paris, France
| | - L du Plessis
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK
| | - M P Verotti
- Coordenação dos Laboratórios de Saúde (CGLAB/DEVIT/SVS), Ministry of Health, Brasília, Brazil
| | - W K de Oliveira
- Coordenação Geral de Vigilância e Resposta às Emergências em Saúde Pública (CGVR/DEVIT), Ministry of Health, Brasília, Brazil.,Center of Data and Knowledge Integration for Health (CIDACS), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil
| | - E H Carmo
- Departamento de Vigilância das Doenças Transmissíveis, Ministry of Health, Brasilia, Brazil
| | - G E Coelho
- Coordenação Geral dos Programas de Controle e Prevenção da Malária e das Doenças Transmitidas pelo Aedes, Ministry of Health, Brasília, Brazil.,Pan American Health Organization (PAHO), Buenos Aires, Argentina
| | - A C F S Santelli
- Coordenação Geral dos Programas de Controle e Prevenção da Malária e das Doenças Transmitidas pelo Aedes, Ministry of Health, Brasília, Brazil.,Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
| | - L C Vinhal
- Coordenação Geral dos Programas de Controle e Prevenção da Malária e das Doenças Transmitidas pelo Aedes, Ministry of Health, Brasília, Brazil
| | - C M Henriques
- Departamento de Vigilância das Doenças Transmissíveis, Ministry of Health, Brasilia, Brazil
| | - J T Simpson
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - M Loose
- University of Nottingham, Nottingham, UK
| | - K G Andersen
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, USA
| | - N D Grubaugh
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, USA
| | - S Somasekar
- Departments of Laboratory Medicine and Medicine &Infectious Diseases, University of California, San Francisco, California, USA
| | - C Y Chiu
- Departments of Laboratory Medicine and Medicine &Infectious Diseases, University of California, San Francisco, California, USA
| | - J E Muñoz-Medina
- División de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
| | - C R Gonzalez-Bonilla
- División de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
| | - C F Arias
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | | | | | - A O Chieppe
- Laboratório Central de Saúde Pública Noel Nutels, Rio de Janeiro, Brazil
| | - S F Aguiar
- Laboratório Central de Saúde Pública Noel Nutels, Rio de Janeiro, Brazil
| | - C A Fernandes
- Laboratório Central de Saúde Pública Noel Nutels, Rio de Janeiro, Brazil
| | - P S Lemos
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - B L S Nascimento
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - H A O Monteiro
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil
| | - I C Siqueira
- Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia, Brazil
| | - M G de Queiroz
- Laboratório Central de Saúde Pública do Estado do Rio Grande do Norte, Natal, Brazil
| | - T R de Souza
- Laboratório Central de Saúde Pública do Estado do Rio Grande do Norte, Natal, Brazil.,Universidade Potiguar do Rio Grande do Norte, Natal, Brazil
| | - J F Bezerra
- Laboratório Central de Saúde Pública do Estado do Rio Grande do Norte, Natal, Brazil.,Faculdade Natalense de Ensino e Cultura, Rio Grande do Norte, Natal, Brazil
| | - M R Lemos
- Laboratório Central de Saúde Pública do Estado da Paraíba, João Pessoa, Brazil
| | - G F Pereira
- Laboratório Central de Saúde Pública do Estado da Paraíba, João Pessoa, Brazil
| | - D Loudal
- Laboratório Central de Saúde Pública do Estado da Paraíba, João Pessoa, Brazil
| | - L C Moura
- Laboratório Central de Saúde Pública do Estado da Paraíba, João Pessoa, Brazil
| | - R Dhalia
- Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil
| | - R F França
- Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil
| | - T Magalhães
- Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil.,Department of Microbiology, Immunology &Pathology, Colorado State University, Fort Collins, Colorado 80523, USA
| | - E T Marques
- Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil
| | - T Jaenisch
- Section Clinical Tropical Medicine, Department for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - G L Wallau
- Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil
| | - M C de Lima
- Laboratório Central de Saúde Pública do Estado de Alagoas, Maceió, Brazil
| | - V Nascimento
- Laboratório Central de Saúde Pública do Estado de Alagoas, Maceió, Brazil
| | - E M de Cerqueira
- Laboratório Central de Saúde Pública do Estado de Alagoas, Maceió, Brazil
| | - M M de Lima
- Universidade Estadual de Feira de Santana, Feira de Santana, Bahia, Brazil
| | - D L Mascarenhas
- Secretaria de Saúde de Feira de Santana, Feira de Santana, Bahia, Brazil
| | | | - A S Levin
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | - T R Tozetto-Mendoza
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | - S N Fonseca
- Hospital São Francisco, Ribeirão Preto, Brazil
| | - M C Mendes-Correa
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | - F P Milagres
- Universidade Federal do Tocantins, Palmas, Brazil
| | - A Segurado
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | | | - A Rambaut
- Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.,Fogarty International Center, National Institutes of Health, Bethesda, Maryland 20892, USA
| | - T Bedford
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - M R T Nunes
- Evandro Chagas Institute, Ministry of Health, Ananindeua, Brazil.,Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555, USA
| | - E C Sabino
- Department of Infectious Disease, School of Medicine &Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil
| | | | - N J Loman
- Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
| | - O G Pybus
- Department of Zoology, University of Oxford, Oxford OX1 3SY, UK.,Metabiota, San Francisco, California 94104, USA
| |
Collapse
|
9
|
Navarrete-Espinosa J, Gonzalez-Ibarra J, Cruz-Tinoco CES, Gonzalez-Bonilla CR, Pacheco-Hernández M, Muñoz-Medina JE. Clinical Behavior of Dengue and Chikungunya Infections in the Instituto Mexicano del Seguro Social. ACTA ACUST UNITED AC 2016. [DOI: 10.4236/ojmm.2016.61005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|